- Home
- FBRX vs PRME Comparison
FBRX vs PRME Comparison
Compare FBRX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBRX | PRME |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 487.2M | 536.4M |
| IPO Year | 2017 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FBRX | PRME |
|---|---|---|
| Price | $21.06 | $3.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.00 | $7.56 |
| AVG Volume (30 Days) | 369.5K | ★ 3.3M |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.30 | 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | $36,000.00 | ★ $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | N/A | $47.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $9.12 | $2.67 |
| 52 Week High | $35.80 | $6.94 |
Technical Indicators
Market Signals| Indicator | FBRX | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 62.98 |
| Support Level | $16.58 | $3.16 |
| Resistance Level | $22.84 | $4.04 |
| Average True Range (ATR) | 1.40 | 0.25 |
| MACD | 0.77 | 0.09 |
| Stochastic Oscillator | 81.45 | 81.10 |
Price Performance
Historical ComparisonAbout FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.